You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

Displaying 1 - 10 of 4034 results
  1. KAPS Biotech: A novel biomarker to improve prostate cancer diagnosis

    SBC: Kaps Biotechnology LLC            Topic: 102

    Abstract Prostate cancer (CaP) is the most common non-skin cancer in men and third most common cause of cancer deaths in men. Black men experience a higher burden of incidence and mortality from CaP compared to White men. The Prostate-Specific Antigen (PSA) test, a commonly used biomarker for early diagnosis and management of CaP, cannot alone accurately predict the presence of CaP, its aggressive ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Developing Nanopieces, a Platform RNAi Delivery Technology for Treatment of Multiple Diseases

    SBC: Nanode Therapeutics, Inc.            Topic: NCATS

    STTR_Developing Nanopieces 7. Project Summary/Abstract The bottleneck of developing new RNAi (RNA Interference) drugs is the lack of highly efficient and non-toxic RNA delivery to non-liver tissues in vivo. It is especially challenging to deliver negatively-charged nucleic acid into avascular, dense, and negatively-charged matrix in hard-to-reach tissues including joint cartilage. NanoDe Therapeut ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Tumor bed implant for simultaneous heat and radiation of resectable brain tumors

    SBC: BrachyThermix LLC            Topic: 100

    Abstract / Summary Glioblastoma multiforme (GBM) is an aggressive brain tumor that generally recurs locally and has a median survival andlt;18 months. Treatment typically involves surgery followed by radiation and chemotherapy but the challenge remains to provide sufficient radiation dose to sterilize tumor bed without unacceptable toxicity in surrounding normal brain. A randomized clinical trial ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Programming Metabolically Fit TILs for Immunotherapy

    SBC: Lipo-immuno Tech, LLC            Topic: NCI

    ABSTRACT Advances in molecular biology and genetic engineering have led to the design and use of modified T cells recognize tumors to achieve significant tumor control upon adoptive cell transfer (ACT) to patients. These T cells are either transduced with tumor antigen reactive T cell receptors (TCR), or chimeric antigen receptors (CARs). Recently, a surge in studies with neo-antigen reactive T ce ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    Abstract Pseudomonas aeruginosa (PA) is the bacterium most frequently isolated from the respiratory tract of ICU pa- tients in the US and is a major cause of pneumonia in intubated patients. Furthermore, infection with PA gener- ally has a poor prognosis, with an estimated 40-69% of PA ventilator-associated pneumonia (VAP) cases re- sulting in mortality, and more than 30% of survivors suffer recur ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Development of EFTX-001 to target KRAS mutations in cancer

    SBC: Enfuego Therapeutics Inc.            Topic: 102

    Research Summary: The KRAS proto-oncogene is one of the most critical genes in cancer, yet it has also proven to be among the most elusive. Nearly all (98%) of KRAS missense mutations occur in codons 12 or 13, which leads to constitutive KRAS activation and promotion of numerous cancer hallmarks. Although kinase inhibitors have revolutionized treatment of some subsets of cancers driven by other mo ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Determination of optimal antisense oligonucleotide chemistry for efficient and safe splicing modulation in T cells

    SBC: Autoimmunity Biologic Solutions, Inc.            Topic: NIAID

    PROJECT SUMMARY Multiple Sclerosis (MS) is the most common neurological disease of early adulthood and is mediated by autoimmune mechanisms that lead to demyelination and neuronal damage in the central nervous system, resulting in progressive neurological dysfunction. There is no cure for the disease and current treatments focus on preventing future immunological attacks, mainly by suppressing the ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Non-Invasive Oropharynx Appliance to Maintain Airway Patency

    SBC: ANEMED LLC            Topic: NHLBI

    Obstructive Sleep Apnea (OSA) is a serious condition that affects about 4% of the population. During sleep, the tongue can fall into the oropharynx and occlude the airways Patients with this condition suffer many instances of apneas (complete cessation of breathing) and hypopneas (period of abnormally low respiratory rate). The apnea- hypopnea index (AHI) gives the number of such episodes per hour ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a vaccine to prevent Pneumocystis pneumonia

    SBC: NXT BIOLOGICS, INC.            Topic: NIAID

    Despite the fact that fungal diseases are an increasing clinical burden, particularly among immunocompromised patients, there are no anti-fungal vaccines approved for clinical use. The fungal opportunistic pathogen, Pneumocystis jirovecii is the causative agent of Pneumocystis pneumonia (PCP), which remains a serious AIDS-defining, opportunistic infection and is of increasing concern in persons re ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Inhaled Fasudil and DETA NONOate CAR-Targeted Liposomes for PAH

    SBC: VASCULAR BIOSCIENCES, INC.            Topic: NHLBI

    Pulmonary arterial hypertension (PAH) affects ~15-50 individuals per million and claims ≥20,000 lives annually in the United States. It affects every ethnic group, race, age and gender, and devastates high-risk patients afflicted with HIV, systemic sclerosis, and sickle cell disease. The disease affects more women than men; adult PAH patients do not live more than five years after the diagnosis. ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government